Novartis | NOVN - Pre Tax Profit



Novartis reported $4.53B in Pre-Tax Profit for its fiscal quarter ending in June of 2025.


Pre Tax Profit Change Date
AbbVie USD 1.66B 3.15B Mar/2025
Alcon AG USD 199M 215M Jun/2025
Almirall EUR 35.8M 37.9M Mar/2025
Amgen USD 1.57B 405M Jun/2025
AstraZeneca USD 3.13B 275M Jun/2025
Autolus Therapeutics Ltd -47520000 20.42M Jun/2025
Bayer EUR -426000000 2.26B Jun/2025
Biogen USD 744M 432.8M Jun/2025
Bristol-Myers Squibb USD 1.77B 1.2B Jun/2025
Eli Lilly USD 6.78B 3.32B Jun/2025
Fresenius EUR 491M 120M Jun/2025
Fresenius Medical Care EUR 350.55M 99.9M Jun/2025
Galapagos EUR -156367000 175.4M Mar/2025
Genmab DKK 423M 179M Jun/2025
Gilead Sciences USD 2.43B 780M Jun/2025
GlaxoSmithKline GBP 1.89B 221M Jun/2025
GRIFOLS EUR 190.51M 20.03M Jun/2025
Hikma Pharmaceutical USD 144M 144M Jun/2024
J&J USD 13.63B 8.21B Mar/2025
Lonza CHF 624M 197M Dec/2024
Merck EUR 829M 127M Jun/2025
Merck USD 6.77B 864M Jun/2025
Novartis USD 4.53B 124M Jun/2025
Novartis USD 4.53B 133M Jun/2025
Novo Nordisk 33.8B 3.23B Jun/2025
Orion EUR 103.4M 26.6M Jun/2025
Pfizer USD 3.04B 259M Jun/2025
Philips EUR 337M 28M Jun/2025
Recordati EUR 119.49M 45.37M Jun/2025
Regeneron Pharmaceuticals USD 1.52B 613.7M Jun/2025
Roche Holding CHF 1.78B 2.33B Dec/2024
Sanofi EUR 1.42B 734M Jun/2025
UCB EUR 1.22B 781M Dec/2024